Even when ERT is started, it can take several months to see improvement in CLN2 scores and biomarkers.13 It is also possible that ERT is prolonging lifespan, which may alter the natural history of disease, resulting in a new “ERT-treated disease phenotype” including a spectrum of movement disorders. The gene discussed is TPP1; the disease is movement disorder.